LIVIVO - Search results -

Search results

Result 1 - 10 of total 39

Search options

Article ; Online: COVID-19 mortality amongst the immunosuppresed.

Moreno-Torres, Víctor / Martínez-Urbistondo, María / Calderón-Parra, Jorge / de Mendoza, Carmen / Soriano, Vicente

2024 Volume 88, Issue 4, Page(s) 106137

MeSH term(s)	Humans ; COVID-19 ; SARS-CoV-2
Language	English
Publishing date	2024-03-11
Publishing country	England
Document type	Letter
ZDB-ID	424417-5
ISSN	1532-2742 ; 0163-4453
ISSN (online)	1532-2742
ISSN	0163-4453
DOI	10.1016/j.jinf.2024.106137
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1501: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 48: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Ceft-to-Ceft Study: Real-Life Experience with Ceftaroline and Ceftobiprole in Treatment of the Principal Infectious Syndromes in a Spanish Multicenter Hospital Cohort.

Arnés García, Daniel / Pitto-Robles, Inés / Calderón Parra, Jorge / Calvo Salvador, Marina / Herrero Rodríguez, Carmen / Gisbert, Laura / Hidalgo-Tenorio, Carmen

Antibiotics (Basel, Switzerland)

2023 Volume 12, Issue 12

Abstract: Background: To compare the real-life effectiveness and safety of ceftaroline fosamil (ceftaroline-F) and ceftobiprole medocaril (ceftobiprole-M) for infections in hospitalized patients.: Methods: This comparative, observational, retrospective, and ... ...

Abstract	Background: To compare the real-life effectiveness and safety of ceftaroline fosamil (ceftaroline-F) and ceftobiprole medocaril (ceftobiprole-M) for infections in hospitalized patients. Methods: This comparative, observational, retrospective, and multicenter Spanish study included patients receiving outpatient parenteral antimicrobial therapy (OPAT) and hospitalized patients treated for at least 48 h with ceftaroline-F or ceftobiprole-M between their first incorporation in the clinical protocol of each hospital and 31 July 2022. Results: Ceftaroline-F was administered to 227 patients and ceftobiprole-M to 212. In comparison to the latter, ceftaroline-F-treated participants were younger (63.02 vs. 66.40 years, OR 1.1; 95%CI: 1.001-1.05) and had higher rates of septic shock (OR 0.27; 95%CI: 0.09-0.81) and higher frequencies of targeted (57.7 vs. 29.7%; OR: 0.35; 95%CI: 0.18-0.69) and combined (89.0 vs. 45.8%, OR: 0.13; 95%CI: 0.06-0.28) therapies that were second line or more (82.4% vs. 64.6%%; OR 0.35; 95%CI: 0.18-0.69), and higher rates of infections due to Gram-positive cocci (92.7 vs. 64.7%, Conclusions: The fifth-generation cephalosporins, ceftaroline-F and ceftobiprole-M, are safe and effective in real life, with no difference between them in health outcomes.
Language	English
Publishing date	2023-12-02
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2681345-2
ISSN	2079-6382
ISSN	2079-6382
DOI	10.3390/antibiotics12121692
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Trends in epidemiology, surgical management, and prognosis of infective endocarditis during the XXI century in Spain: A population-based nationwide study.

Calderón-Parra, Jorge / Gutiérrez-Villanueva, Andrea / Yagüe-Diego, Itziar / Cobo, Marta / Domínguez, Fernando / Forteza, Alberto / Ana, Fernández-Cruz / Muñez-Rubio, Elena / Moreno-Torres, Victor / Ramos-Martínez, Antonio

Journal of infection and public health

2024 Volume 17, Issue 5, Page(s) 881–888

Abstract: Background: Few population-based studies have evaluated the epidemiology of infective endocarditis (IE). Changes in population demographics and guidelines on IE may have affected both the incidence and outcomes of IE. Therefore, the aim of our study is ... ...

Abstract	Background: Few population-based studies have evaluated the epidemiology of infective endocarditis (IE). Changes in population demographics and guidelines on IE may have affected both the incidence and outcomes of IE. Therefore, the aim of our study is to provide contemporary population-based epidemiological data of IE in Spain. Methods: Retrospective nationwide observational study using data from the Spanish National Health System Discharge Database. We included all patients hospitalized with IE from January 2000 to December 2019. Results: A total of 64,550 IE episodes were included. The incidence of IE rose from 5.25 cases/100,000 person-year in 2000 to 7.21 in 2019, with a 2% annual percentage change (95% CI 1.3-2.6). IE incidence was higher among those aged 85 or older (43.5 cases/100.000 person-years). Trends across the study period varied with sex and age. Patients with IE were progressively older (63.9 years in 2000-2004 to 70.0 in 2015-2019, p < 0.001) and had more frequent comorbidities and predispositions, including, previous valvular prosthesis (12.1% vs 20.9%, p < 0.001). After adjustment, a progressive reduction in mortality was noted including in 2015-2019 compared to 2010-2014 (adjusted odds ratio 0.93, 95% confident interval 0.88-0.99, p = 0.023)., which was associated with more frequent cardiac surgery in recent years (15.1% in 2010-2014 vs 19.9% in 2015-2019). Conclusions: In Spain, the incidence of IE has increased during the XXI century, with a more pronounced increase in elderly individuals. Adjusted-mortality decreased over the years, which could be related to a higher percentage of surgery. Our results highlight the changing epidemiology of IE.
MeSH term(s)	Aged ; Humans ; Spain/epidemiology ; Retrospective Studies ; Endocarditis, Bacterial/epidemiology ; Endocarditis, Bacterial/surgery ; Endocarditis/epidemiology ; Endocarditis/surgery ; Prognosis ; Incidence
Language	English
Publishing date	2024-03-13
Publishing country	England
Document type	Observational Study ; Journal Article
ZDB-ID	2467587-8
ISSN	1876-035X ; 1876-0341
ISSN (online)	1876-035X
ISSN	1876-0341
DOI	10.1016/j.jiph.2024.03.011
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Re: 'the unique COVID-19 presentation of patients with B cell depletion' by Belkin et al.

Múñez-Rubio, Elena / Calderón-Parra, Jorge / Fernández-Cruz, Ana / Moreno-Torres, Víctor / Blanco-Alonso, Silvia / Ramos-Martínez, Antonio

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

2022 Volume 29, Issue 2, Page(s) 272–273

MeSH term(s)	Humans ; COVID-19/diagnosis ; SARS-CoV-2
Language	English
Publishing date	2022-10-27
Publishing country	England
Document type	Letter ; Comment
ZDB-ID	1328418-6
ISSN	1469-0691 ; 1470-9465 ; 1198-743X
ISSN (online)	1469-0691
ISSN	1470-9465 ; 1198-743X
DOI	10.1016/j.cmi.2022.10.025
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4541: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 284: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Efficacy and safety of antiviral plus anti-spike monoclonal antibody combination therapy vs. monotherapy for high-risk immunocompromised patients with mild-to-moderate SARS-CoV2 infection during the Omicron era: A prospective cohort study.

Calderón-Parra, Jorge / Gutiérrez-Villanueva, Andrea / Ronda-Roca, Gerard / Jimenez, Maria Luisa Martín / de la Torre, Helena / Ródenas-Baquero, María / Paniura-Pinedo, María / Lozano-Llano, Carla / Pintos-Pascual, Ilduara / Fernández-Cruz, Ana / Ramos-Martínez, Antonio / Muñez-Rubio, Elena

International journal of antimicrobial agents

2024 Volume 63, Issue 3, Page(s) 107095

Abstract: Introduction: Antivirals and monoclonal antibodies lower the risk of progression in immunocompromised patients. However, combination therapy with both types of agents has not been studied.: Patients and methods: This was a single-centre, prospective, ...

Abstract	Introduction: Antivirals and monoclonal antibodies lower the risk of progression in immunocompromised patients. However, combination therapy with both types of agents has not been studied. Patients and methods: This was a single-centre, prospective, cohort study. All immunocompromised patients who received treatment for mild-to-moderate COVID-19 from 1 January 2022 to 30 October 2022 were enrolled. The primary endpoint was COVID-19 progression at 90 days, defined as hospital admission or death due to COVID-19 and/or seronegative persistent COVID-19. Results: A total of 304 patients were included: 43 patients (14.1%) received sotrovimab plus a direct-acting antiviral, and 261 (85.9%) received monotherapy. Primary outcome occurred more frequently after monotherapy (4.6% vs. 0%, P=0.154). Among patients with anti-spike immunoglobulin G (anti-S IgG) titre <750 BAU/mL, COVID-19 progression was more common after monotherapy (23.9% vs. 0%, P=0.001), including more frequent COVID-related admission (15.2% vs. 0%, P=0.014) and seronegative persistent COVID-19 (10.9% vs. 0%, P=0.044). Combination therapy was associated with lower risk of progression (odds ratio [OR] 0.08, 95% confidence interval [95% CI] 0.01-0.64). Anti-S IgG titre <750 BAU/mL and previous anti-CD20 were associated with higher risk of progression (OR 13.70, 95% CI 2.77-67.68; and OR 3.05, 95% CI 1.20-10.94, respectively). Conclusions: In immunocompromised patients, combination therapy with sotrovimab plus an antiviral may be more effective than monotherapy for SARS-CoV2.
MeSH term(s)	Humans ; Prospective Studies ; RNA, Viral ; Antiviral Agents/therapeutic use ; Cohort Studies ; COVID-19 ; Hepatitis C, Chronic ; SARS-CoV-2 ; Antibodies, Monoclonal/adverse effects ; Immunocompromised Host ; Immunoglobulin G
Chemical Substances	RNA, Viral ; Antiviral Agents ; Antibodies, Monoclonal ; Immunoglobulin G
Language	English
Publishing date	2024-01-18
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	1093977-5
ISSN	1872-7913 ; 0924-8579
ISSN (online)	1872-7913
ISSN	0924-8579
DOI	10.1016/j.ijantimicag.2024.107095
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3368: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 500: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Risk of Infective Endocarditis Associated with Transcatheter Aortic Valve Implantation versus Surgical Aortic Valve Replacement: A Propensity Score-Based Analysis.

Calderón-Parra, Jorge / de Villarreal-Soto, Juan E / Oteo-Domínguez, Juan Francisco / Mateos-Seirul, María / Ríos-Rosado, Elsa / Dorado, Laura / Vera-Puente, Beatriz / Arellano-Serrano, Carlos / Ramos-Martínez, Antonio / Forteza-Gil, Alberto

Journal of clinical medicine

2023 Volume 12, Issue 2

Abstract: Background: Infective endocarditis (IE) is a feared complication after surgical aortic valve replacement (SAVR)/transcatheter aortic valve implantation (TAVI). It is not certain which procedure carries a higher risk. Our aim was to assess the risk of IE ... ...

Abstract	Background: Infective endocarditis (IE) is a feared complication after surgical aortic valve replacement (SAVR)/transcatheter aortic valve implantation (TAVI). It is not certain which procedure carries a higher risk. Our aim was to assess the risk of IE after SAVR/TAVI. Methods: We conducted an observational study of a prospective cohort, including patients with TAVI/SAVR, from March 2015 to December 2020. IE was defined according to the modified Duke’s criteria. IE occurring during the first 12 months of the procedure was considered early IE, and an episode occurring after 12 months was considered late IE. The propensity score was designed to include variables previously associated with TAVI/SAVR and IE. An inverse probability of treatment weight was generated. Results: In total, 355 SAVR and 278 TAVI were included. Median follow-up, 38 vs. 41 months, p = 0.550. IE occurred in 5 SAVR (1.41%, 95% CI 0.2−2.6) vs. 13 TAVI (4.65%, 95% CI 2.2−7.2), p = 0.016. TAVI patients had more frequent early IE (3.2% vs. 0.3%, p = 0.006). In the PS analyses, IE risk did not differ: OR 0.65, 95% CI 0.32−1.32. Factors associated with TAVI IE included younger age (74y vs. 83y, p = 0.030), complicated diabetes mellitus (38.5% vs. 6.8%, p = 0.002), COPD (46.2% vs. 16.3%, p = 0.015), advanced heart failure (100% vs. 52.9%, p < 0.001), and peripheral arteriopathy (61.5% vs. 26.7%, p = 0.011). Conclusions: Early IE was higher with TAVI, but in the PS analyses, the risk attributable to each procedure was similar. Studies are needed to identify and optimize the risk factors of IE prior to TAVI.
Language	English
Publishing date	2023-01-11
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2662592-1
ISSN	2077-0383
ISSN	2077-0383
DOI	10.3390/jcm12020586
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Determining the usefulness of systematic

Gutiérrez, Andrea / Rodriguez, Begoña / Velasquez, Karina / Gutiérrez, Isabel / García, Sonia / Múñez, Elena / Calderón-Parra, Jorge / Callejas-Diaz, Alejandro / Ramos-Martinez, Antonio / Fernandez-Cruz, Ana

BMJ open

2023 Volume 13, Issue 6, Page(s) e074240

Abstract: Introduction: The evaluation of staging and activity of invasive fungal infection (IFI) is used to adjust the type and duration of antifungal therapy (AT). Typically anatomy-based imaging is used. Positron emission tomography/CT with : Methods and ... ...

Abstract	Introduction: The evaluation of staging and activity of invasive fungal infection (IFI) is used to adjust the type and duration of antifungal therapy (AT). Typically anatomy-based imaging is used. Positron emission tomography/CT with Methods and analysis: Multicentre prospective cohort study of IFI with performance of systematic Ethics and dissemination: The Clinical Research Ethics Committee of Puerta de Hierro-Majadahonda University Hospital approved the protocol of the study at the primary site. We plan to publish the results in high-impact journals. Trial registration number: NCT05688592.
MeSH term(s)	Humans ; Fluorodeoxyglucose F18 ; Invasive Fungal Infections/diagnostic imaging ; Invasive Fungal Infections/drug therapy ; Multicenter Studies as Topic ; Neoplasm Staging ; Positron Emission Tomography Computed Tomography ; Positron-Emission Tomography ; Prospective Studies ; Radiopharmaceuticals
Chemical Substances	Fluorodeoxyglucose F18 (0Z5B2CJX4D) ; Radiopharmaceuticals
Language	English
Publishing date	2023-06-23
Publishing country	England
Document type	Clinical Trial Protocol ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2599832-8
ISSN	2044-6055 ; 2044-6055
ISSN (online)	2044-6055
ISSN	2044-6055
DOI	10.1136/bmjopen-2023-074240
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Increased incidence of giant cell arteritis and associated stroke during the COVID-19 pandemic in Spain: A nation-wide population study.

Moreno-Torres, Víctor / Soriano, Vicente / Calderón-Parra, Jorge / Martínez-Urbistondo, María / Treviño, Ana / de San Vicente, Zayrho / de Mendoza, Carmen / Ruiz-Irastorza, Guillermo

Autoimmunity reviews

2023 Volume 22, Issue 6, Page(s) 103341

Abstract: Introduction: SARS-CoV-2 infection and COVID-19 vaccines might have increased the incidence of giant-cell arteritis (GCA) and the risk of associated stroke in Spain.: Methods: Retrospective nation-wide observational analysis of all adults ... ...

Abstract	Introduction: SARS-CoV-2 infection and COVID-19 vaccines might have increased the incidence of giant-cell arteritis (GCA) and the risk of associated stroke in Spain. Methods: Retrospective nation-wide observational analysis of all adults hospitalized with GCA in Spain during 5 years (Jan-2016 and Dec-2021). The incidence and proportion of admissions with or because of GCA and GCA-associated stroke were compared between pre-pandemic (2016-2019) and pandemic (2020 and 2021) years. Sensitivity analyses were conducted for the different COVID-19 waves and vaccine timing schedules. Results: A total of 17,268 hospital admissions in patients diagnosed with GCA were identified. During 2020 there were 79.3 and 8.1 per 100,000 admissions of GCA and GCA-associated stroke, respectively. During 2021 these figures were 80.8 and 7.7 per 100,00 admissions, respectively. As comparison, yearly admissions due to GCA and GCA-associated stroke were 72.4 and 5.7 per 100,00, respectively, during the pre-pandemic period (p < 0.05). Coincident with the third wave of COVID-19 (and first vaccine dosing), the rate of GCA-associated stroke admissions increased significantly (from 6.7 to 12%; p < 0.001). Likewise, there was an increase in GCA-associated stroke (6.6% vs 4.1%, p = 0.016) coincident with the third dose vaccination (booster) in patients older than 70 at the end of 2021. In multivariate analysis, only patients admitted during the third COVID-19 wave (and first vaccine dosing) (OR = 1.89, 95% CI 1.22-2.93), and during the third vaccination dosing in patients older than 70 (booster) (OR = 1.66, CI 1.11-2.49), presented a higher GCA-associated stroke risk than the same months of previous years after adjustment by age, sex, classical cardiovascular risk factors and COVID-19 diagnosis. Conclusions: The COVID-19 pandemic led to an increased incidence of GCA during 2020 and 2021. Moreover, the risk of associated stroke significantly risen accompanying times of COVID-19 vaccine dosing, hypothetically linked to an increased thrombotic risk of mRNA-SARS-CoV-2 vaccines. Hence, forthcoming vaccine policies and indications must weigh the risk of severe COVID-19 with the risk of flare or stroke in patients with GCA.
MeSH term(s)	Humans ; Giant Cell Arteritis/complications ; Giant Cell Arteritis/epidemiology ; Giant Cell Arteritis/diagnosis ; COVID-19 Vaccines ; Retrospective Studies ; Pandemics ; Incidence ; Spain/epidemiology ; COVID-19 Testing ; COVID-19/complications ; COVID-19/epidemiology ; SARS-CoV-2 ; Stroke/etiology ; Stroke/complications
Chemical Substances	COVID-19 Vaccines
Language	English
Publishing date	2023-04-14
Publishing country	Netherlands
Document type	Journal Article ; Review
ZDB-ID	2144145-5
ISSN	1873-0183 ; 1568-9972
ISSN (online)	1873-0183
ISSN	1568-9972
DOI	10.1016/j.autrev.2023.103341
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5913: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Epidemiology and Risk Factors of Mycotic Aneurysm in Patients With Infective Endocarditis and the Impact of its Rupture in Outcomes. Analysis of a National Prospective Cohort.

Calderón-Parra, Jorge / Domínguez, Fernando / González-Rico, Claudia / Arnaiz de Las Revillas, Francisco / Goenaga, Miguel Ángel / Alvarez, I / Muñoz, Patricia / Alonso, David / Rodríguez-García, Raquel / Miró, José María / De Alarcón, Arístides / Antorrena, Isabel / Goikoetxea-Agirre, Josune / Moral-Escudero, Encarnación / Ojeda-Burgos, Guillermo / Ramos-Martínez, Antonio

Open forum infectious diseases

2024 Volume 11, Issue 3, Page(s) ofae121

Abstract: Background: Several aspects of the occurrence and management of mycotic aneurysm (MA) in patients with infective endocarditis (IE) have not been studied.: Objectives: To determine the incidence and factors associated with MA presence and rupture and ... ...

Abstract	Background: Several aspects of the occurrence and management of mycotic aneurysm (MA) in patients with infective endocarditis (IE) have not been studied. Objectives: To determine the incidence and factors associated with MA presence and rupture and to assess the evolution of those initially unruptured MA. Methods: Prospective multicenter cohort including all patients with definite IE between January 2008 and December 2020. Results: Of 4548 IE cases, 85 (1.9%) developed MA. Forty-six (54.1%) had intracranial MA and 39 (45.9%) extracranial MA. Rupture of MA occurred in 39 patients (45.9%). Patients with ruptured MA had higher 1-year mortality (hazard ratio, 2.33; 95% confidence interval, 1.49-3.67). Of the 55 patients with initially unruptured MA, 9 (16.4%) presented rupture after a median of 3 days (interquartile range, 1-7) after diagnosis, being more frequent in intracranial MA (32% vs 3.3%, Conclusions: MA occurred in 2% of the patients with IE. Half of the Mas occurred in an intracranial location. Their rupture is frequent and associated with poor prognosis. A significant proportion of initially unruptured aneurysms result from rupture during the first several days, being more common in intracranial aneurysms. Early specific treatment could potentially lead to better outcomes.
Language	English
Publishing date	2024-03-13
Publishing country	United States
Document type	Clinical Trial
ZDB-ID	2757767-3
ISSN	2328-8957
ISSN	2328-8957
DOI	10.1093/ofid/ofae121
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Use of Monoclonal Antibodies in Immunocompromised Patients Hospitalized with Severe COVID-19: A Retrospective Multicenter Cohort.

Calderón-Parra, Jorge / Guisado-Vasco, Pablo / Montejano-Sánchez, Rocío / Estrada, Vicente / Cuevas-Tascón, Guillermo / Aguareles, José / Arribas, José / Erro-Iribarren, Marta / Calvo-Salvador, Marina / Fernández-Cruz, Ana / Ramos-Martínez, Antonio / Muñez-Rubio, Elena

Journal of clinical medicine

2023 Volume 12, Issue 3

Abstract: Objective: We aim to describe the safety and efficacy of sotrovimab in severe cases of COVID-19 in immunocompromised hosts.: Methods: We used a retrospective multicenter cohort including immunocompromised hospitalized patients with severe COVID-19 ... ...

Abstract	Objective: We aim to describe the safety and efficacy of sotrovimab in severe cases of COVID-19 in immunocompromised hosts. Methods: We used a retrospective multicenter cohort including immunocompromised hospitalized patients with severe COVID-19 treated with sotrovimab between October 2021 and December 2021. Results: We included 32 patients. The main immunocompromising conditions were solid organ transplantation (46.9%) and hematological malignancy (37.5%). Seven patients (21.9%) had respiratory progression: 12.5% died and 9.4% required mechanical ventilation. Patients treated within the first 14 days of their symptoms had a lower progression rate: 12.0% vs. 57.1%, Conclusions: Sotrovimab was safe and may be effective in its use for immunocompromised patients with severe COVID-19. More studies are needed to confirm these preliminary data.
Language	English
Publishing date	2023-01-21
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2662592-1
ISSN	2077-0383
ISSN	2077-0383
DOI	10.3390/jcm12030864
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito